anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
Kymera Therapeutics · pitchdeck

Kymera | Investor Presentation Deck | 46 slides

46 pages · 4 arc beats · 2 loops

Pitchdeck Download JSON
Unlock

Kymera | Investor Presentation Deck | 46 slides

Kymera Therapeutics · 2023-12
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

4
coverage by narrative range · generated from this deck JSON
Narrative range 46 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Attention 3 slides 100% 3/3 slides 100% 3/3 slides · 9 hits
— 0/3 slides
66.7% 2/3 slides
— 0/3 slides
100% 3/3 slides
— 0/3 slides
Interest 3 slides 100% 3/3 slides 100% 3/3 slides · 14 hits
— 0/3 slides
66.7% 2/3 slides 66.7% 2/3 slides 100% 3/3 slides 66.7% 2/3 slides Desire 14 slides 100% 14/14 slides 100% 14/14 slides · 65 hits
— 0/14 slides
28.6% 4/14 slides 14.3% 2/14 slides 100% 14/14 slides 100% 14/14 slides · 28 hits Action 26 slides 100% 26/26 slides 100% 26/26 slides · 117 hits
— 0/26 slides
34.6% 9/26 slides · 11 hits 23.1% 6/26 slides 100% 26/26 slides
— 0/26 slides

Slide inventory

46
every slide · same image gating as the playbook
01
Slide 1
Includes company logo and date.front_matter
Open slide detailBeat · Attention
02
other
Open slide detailBeat · Attention
03
summarize
Open slide detailBeat · Attention
04
show_traction
Open slide detailBeat · Interest
05
TPD stands for Targeted Protein Degradation. The slide uses a three-column framework to explain their competitive advantage.present_solution
Open slide detailBeat · InterestLoop · Logic Chain
06
The slide uses a standard pharmaceutical pipeline table format.plan_implementation
Open slide detailBeat · InterestLoop · Logic Chain
07
This is a stylistic section divider slide with an abstract background.transition
Open slide detailBeat · DesireLoop · Logic Chain
08
The slide uses a biological pathway diagram to illustrate the mechanism of action for a drug candidate.present_solution
Open slide detailBeat · DesireLoop · Logic Chain
09
Includes a mechanism of action diagram, a market data table, and a callout box on competitive limitations.size_opportunity
Open slide detailBeat · DesireLoop · Logic Chain
10
Comparison of two distinct cohorts: Healthy Volunteers (SAD/MAD) vs. HS/AD Patient Cohort.show_traction
Open slide detailBeat · DesireLoop · Logic Chain
11
Includes both a longitudinal line chart for IRAK4 degradation and a grouped bar chart with a supporting data table for cytokine inhibition.analyze_data
Open slide detailBeat · DesireLoop · Logic Chain
12
Includes PK/PD correlation, blood IRAK4 levels, skin exposure, and skin lesion IRAK4 reduction data.show_traction
Open slide detailBeat · DesireLoop · Logic Chain
13
The charts show log2(fold change) for individual patients. The footnote defines the log2(fold change) values in terms of percentage decrease.analyze_data
Open slide detailBeat · DesireLoop · Logic Chain
14
Data compares 'All HS Patients' vs 'Moderate to Severe' subgroups across four metrics over 42 days.show_traction
Open slide detailBeat · DesireLoop · Logic Chain
15
The slide includes a disclaimer that the comparison is not head-to-head and uses historical benchmarks.compare_peers
Open slide detailBeat · DesireLoop · Logic Chain
16
Data presented as mean +/- S.E. of mean; N=7 patients.show_traction
Open slide detailBeat · DesireLoop · Logic Chain
17
The slide includes a disclaimer regarding the non-head-to-head nature of the comparison.compare_peers
Open slide detailBeat · DesireLoop · Logic Chain
18
The slide provides clinical safety data for the KT-474 drug candidate.analyze_data
Open slide detailBeat · DesireLoop · Logic Chain
19
The slide outlines the status of a partnership with Sanofi and clinical trial timelines.show_traction
Open slide detailBeat · DesireLoop · Logic Chain
20
Includes clinical trial identifiers and definitions of acronyms in the footer.analyze_data
Open slide detailBeat · DesireLoop · Logic Chain
21
transition
Open slide detailBeat · Action
22
Includes a table of market data and a biological pathway diagram.present_solution
Open slide detailBeat · Action
23
Includes PK/PD data and efficacy metrics in multiple T-cell lymphoma models.show_traction
Open slide detailBeat · Action
24
Includes box plots for gene expression and a tumor volume growth curve over time.show_traction
Open slide detailBeat · Action
25
The slide uses a process flow diagram to illustrate the transition from dose escalation (DL1-DLx) to expansion cohorts for specific indications.plan_implementation
Open slide detailBeat · Action
26
transition
Open slide detailBeat · Action
27
Data cut-off: 18 October 2023. Includes breakdown by age, sex, ECOG status, prior therapy, and tumor type.analyze_data
Open slide detailBeat · Action
28
Clinical trial safety data summary.summarize
Open slide detailBeat · Action
29
The table tracks clinical trial outcomes (PR: Partial Response, SD: Stable Disease, PD: Progressive Disease) for a drug candidate.show_traction
Open slide detailBeat · Action
30
Includes both tabular summary of dose-level degradation and visual histology/bar chart evidence of tumor reduction.show_traction
Open slide detailBeat · Action
31
Includes longitudinal line charts for blood mRNA levels and a bar chart/enrichment plot for tumor response.show_traction
Open slide detailBeat · Action
32
The slide uses a split-layout: left side for clinical data results, right side for strategic opportunity/implications.show_traction
Open slide detailBeat · Action
33
transition
Open slide detailBeat · Action
34
Includes a waterfall plot showing p53WT cell dependency on MDM2 and a biological process diagram of the MDM2-p53 feedback loop.present_solution
Open slide detailBeat · Action
35
Includes three dose-response curves and a comparative table of clinical stage and potency metrics.compare_peers
Open slide detailBeat · Action
36
Comparison of protein levels and tumor volume over time across multiple dosing regimens.show_traction
Open slide detailBeat · Action
37
The slide uses a standard clinical trial dose-escalation diagram and a demographic table.analyze_data
Open slide detailBeat · Action
38
The slide uses a biological mechanism diagram on the left and clinical data (table and line chart) on the right to validate the drug's mechanism of action.show_traction
Open slide detailBeat · Action
39
The chart is a swimmer plot, a standard tool in oncology clinical trials to visualize duration of response.show_traction
Open slide detailBeat · Action
40
Clinical trial safety reporting slide.show_traction
Open slide detailBeat · Action
41
The slide uses a split-layout comparing technical mechanism/data (left) with strategic opportunity (right).show_traction
Open slide detailBeat · Action
42
plan_implementation
Open slide detailBeat · Action
43
This is a standard closing slide for an investor presentation.state_next_steps
Open slide detailBeat · Action
44
appendix
Open slide detailBeat · Action
45
The table displays patient counts and percentages for specific adverse events categorized by dose level (DL1-DL5) and overall.analyze_data
Open slide detailBeat · Action
46
Includes both a summary table of response categories and a swimmer plot for treatment duration.show_traction
Open slide detailBeat · Action